NANTES, FRANCE--(Marketwire - June 8, 2010) - VIVALIS (NYSE Euronext: VLS) announced today the signature with Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext: SAN and NYSE: SNY ...

Vivalis and Intercell have agreed to the terms of a merger to create a new European biotechnology company called Valneva that will specialize in vaccines and antibodies. Vivalis and Intercell have ...

Vivalis strengthens its management team with the appointment of Philippe Rousseau, as Chief Financial Officer VIVALIS (PARIS: VLS), a biopharmaceutical company that provides the pharmaceutical ...

Vivalis shareholders will own 55% of Valneva, with Intercell’s shares being converted at a 39% premium to the pre-deal share prices. An extra 8.6m shares will be issued to former Intercell ...

PARIS, Nov 24 (Reuters) - French biotech firm Vivalis and British partner GlaxoSmithKline have won U.S. clearance to begin testing on humans for the first time flu vaccines which were produced using ...

ATLANTA and NANTES, France, July 22 GeoVax Labs,Inc. (OTC Bulletin Board: GOVX), an Atlanta based, biopharmaceutical companydeveloping human vaccines for diseases caused by HIV-1 (Human ...

On 16 December 2012, Vivalis SA and Intercell AG have announced their intention to merge and form Valneva SE (“Valneva”). The merger is progressing well, in line with the timeline communicated at time ...

Firm is developing VLP-based vaccines. Vivalis has granted Novavax the right to use its EB66® cell line for the production of VLP-based vaccines against several new potential viruses. The EB66 cell ...

French-owned Vivalis will acquire Austria’s Intercell for about €133 million ($174 million), in a merger intended to create a stronger developer of anti-infective treatments. The merged company, to be ...

FRENCH biotech firm Vivalis and its British partner GlaxoSmithKline have won US clearance to begin testing for the first time on humans flu vaccines that were produced using Vivalis’s technology.

LONDON/PARIS (Reuters) - France's Vivalis and Austrian vaccine specialist Intercell are linking up in a rare cross-border deal that shows the need for Europe's fledgling biotech companies to grow in ...